| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 |
| filingDate |
2010-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012517989-A |
| titleOfInvention |
Combination of avermectin or milbemycin and adrenergic receptor for treating or preventing skin diseases |
| abstract |
The present invention relates to a combination of compounds for treating skin diseases, particularly rosacea and ocular rosacea. The present invention relates to combinations of avermectin family compounds or milbemycin family compounds with alpha-1 or alpha-2 adrenergic receptor agonist family compounds. The present invention further provides: (a) avermectin family compound or milbemycin family compound as a combination of products for application as a medicament for treating and / or preventing skin diseases, particularly rosacea and ocular rosacea A product in the form of a kit comprising: a first composition comprising: and (b) a second composition comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family different from the first composition, The first and second compositions can be applied simultaneously, separately or with a time delay. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016538311-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019031572-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014533271-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017140028-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019523291-A |
| priorityDate |
2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |